Carrier L. Targeting the population for gene therapy with MYBPC3. J Mol Cell Cardiol. 2021;150:101–8.
Cirino AL, Harris SL, Murad AM, Hansen B, Malinowski J, Natoli JL, et al. The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—A systematic review and meta-analysis. J Genet Couns. 2022;31:1290–305.
Ariga R, Tunnicliffe EM, Manohar SG, Mahmod M, Raman B, Piechnik SK, et al. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias. J Am Coll Cardiol. 2019;73:2493–502.
Marian AJ, Asatryan B, Wehrens XHT. Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. Cardiovasc Res. 2020;116:1600–19.
Tudurachi BS, Zăvoi A, Leonte A, Țăpoi L, Ureche C, Bîrgoan SG, et al. An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy. Int J Mol Sci. 2023;24:10510.
Schlossarek S, Mearini G, Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: Mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2011;50:613–20.
Alders M. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848–53.
Helms AS, Thompson AD, Glazier AA, Hafeez N, Kabani S, Rodriguez J, et al. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020;13:396–405.
Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121:749–70.
Ribeiro M, Furtado M, Martins S, Carvalho T, Carmo-Fonseca M. RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy. Int J Mol Sci. 2020;21:1329.
Ito K, Patel PN, Gorham JM, McDonough B, DePalma SR, Adler EE, et al. Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing. Proc Natl Acad Sci. 2017;114:7689–94.
Frank-Hansen R, Page SP, Syrris P, McKenna WJ, Christiansen M, Andersen PS. Micro-exons of the cardiac myosin binding protein C gene: flanking introns contain a disproportionately large number of hypertrophic cardiomyopathy mutations. Eur J Hum Genet. 2008;16:1062–9.
Torrado M, Maneiro E, Lamounier Junior A, Fernández-Burriel M, Sánchez Giralt S, Martínez-Carapeto A, et al. Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree. Sci Rep. 2022;12:7284.
Caroselli S, Fabiani M, Micolonghi C, Savio C, Tini G, Musumeci B, et al. Reanalysis of Next-generation Sequencing Data in Patients With Hypertrophic Cardiomyopathy: Contribution of Spliceogenic MYBPC3 Variants in an Italian Cohort. Ann Lab Med. 2025;45:96–100.
Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F, et al. A molecular screening strategy based on β-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med. 2006;7:601–7.
Calore C, De Bortoli M, Romualdi C, Lorenzon A, Angelini A, Basso C, et al. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. J Med Genet. 2015;52:338–47.
Vodnjov N, Maver A, Teran N, Peterlin B, Toplišek J, Writzl K. Clinical Outcome of Hypertrophic Cardiomyopathy in Probands with the Founder Variant c.913_914del in MYBPC3: A Slovenian Cohort Study. J Cardiovasc Transl Res [Internet]. 2024 Aug [cited 2024 Dec 12]; Available from: https://link.springer.com/10.1007/s12265-024-10551-5.
Adalsteinsdottir B, Burke M, Maron BJ, Danielsen R, Lopez B, Diez J, et al. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart. 2020;7:e001220.
Redin C, Pavlidou DC, Bhuiyan Z, Porretta AP, Monney P, Bedoni N, et al. The «Amish» NM_000256.3:c.3330+2T>G splice variant in MYBPC3 associated with hypertrophic cardiomyopathy is an ancient Swiss mutation. Eur J Med Genet. 2022;65:1204627.
Boen HM, Alaerts M, Van Laer L, Saenen JB, Goovaerts I, Bastianen J, et al. Phenotypic spectrum of the first Belgian MYBPC3 founder: a large multi-exon deletion with a varying phenotype. Front Genet. 2024;15:1392527.
Coppini R, Ho CY, Ashley E, Day S, Ferrantini C, Girolami F, et al. Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations. J Am Coll Cardiol. 2014;64:2589–600.
Roncarati R, Latronico MVG, Musumeci B, Aurino S, Torella A, Bang M, et al. Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in italian patients with hypertrophic cardiomyopathy. J Cell Physiol. 2011;226:2894–900.
Cecconi M, Parodi MI, Formisano F, Spirito P, Autore C, Musumeci MB, et al. Targeted next-generation sequencing helps to decipher the genetic and phenotypic heterogeneity of hypertrophic cardiomyopathy. Int J Mol Med. 2016;38:1111–24.
Rubattu S, Bozzao C, Pennacchini E, Pagannone E, Musumeci B, Piane M, et al. A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. Int J Mol Sci. 2016;17:1239.
Sabater-Molina M, Saura D, García-Molina Sáez E, González-Carrillo J, Polo L, Pérez-Sánchez I, et al. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. Rev Esp Cardiol Engl Ed. 2017;70:105–14.
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503–626.
Micolonghi C, Perrone F, Fabiani M, Caroselli S, Savio C, Pizzuti A, et al. Unveiling the Spectrum of Minor Genes in Cardiomyopathies: A Narrative Review. Int J Mol Sci. 2024;25:9787.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
Barrett JC. Haploview: Visualization and Analysis of SNP Genotype Data. Cold Spring Harb Protoc. 2009;2009:pdb.ip71.
Duan S, Zhang W, Cox NJ, Dolan ME. FstSNP-HapMap3: a database of SNPs with high population differentiation for HapMap3. Bioinformation. 2008;3:139–41.
Little S. Amplification-Refractory Mutation System (ARMS) Analysis of Point Mutations. Curr Protoc Hum Genet [Internet]. 1995 Nov [cited 2024 Dec 12];7. Available from: https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/0471142905.hg0908s07.
Mertes C, Scheller IF, Yépez VA, Çelik MH, Liang Y, Kremer LS, et al. Detection of aberrant splicing events in RNA-seq data using FRASER. Nat Commun. 2021;12:529.
Holliday M, Singer ES, Ross SB, Lim S, Lal S, Ingles J, et al. Transcriptome Sequencing of Patients With Hypertrophic Cardiomyopathy Reveals Novel Splice-Altering Variants in MYBPC3. Circ Genom Precis Med. 2021;14:e003202.
Slatkin M, Rannala B. Estimating the age of alleles by use of intraallelic variability. Am J Hum Genet. 1997;60:447–58.
Genin E, Tullio-Pelet A, Begeot F, Lyonnet S, Abel L. Estimating the age of rare disease mutations: the example of Triple-A syndrome. J Med Genet. 2004;41:445–9.
Adalsteinsdottir B, Teekakirikul P, Maron BJ, Burke MA, Gudbjartsson DF, Holm H, et al. Nationwide Study on Hypertrophic Cardiomyopathy in Iceland: Evidence of a MYBPC3 Founder Mutation. Circulation. 2014;130:1158–67.
Christiaans I, Nannenberg EA, Dooijes D, Jongbloed RJE, Michels M, Postema PG, et al. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J. 2010;18:248–54.
Méndez I, Fernández AI, Espinosa MÁ, Cuenca S, Lorca R, Rodríguez JF, et al. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males. Open Heart. 2021;8:e001789.
Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2005;46:480–7.
Pioner JM, Vitale G, Steczina S, Langione M, Margara F, Santini L, et al. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM. Circ Res. 2023;132:628–44.
Jansen M, Schmidt AF, Jans JJM, Christiaans I, Van Der Crabben SN, Hoedemaekers YM, et al. Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers. J Cardiovasc Transl Res. 2023;16:1267–75.
Lorca R, Gómez J, Martín M, Cabanillas R, Calvo J, León V, et al. Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant. Rev Esp Cardiol Engl Ed. 2019;72:138–44.